CureDuchenne to Host a Webinar on Duchenne Muscular Dystrophy Research with Dr. Kevin Flanigan from Nationwide Children’s Hospital on November 21

NEWPORT BEACH, Calif., November 14, 2013: CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host a “New Duplication Exon 2 Mouse Model: A Tool for Studies of Duplication Skipping for Duchenne” webinar with Dr. Kevin Flanigan from Nationwide Children’s Hospital on Thursday, November 21 at noon EST/9:00 a.m. PST. The webinar is an opportunity for the Duchenne community to learn about the duplication mutation research and an exciting exon skipping method using AAV delivery with U7. CureDuchenne has provided the lead funding for Dr. Flanigan’s duplication research.

Flanigan, MD, is an attending neurologist at Nationwide Children’s and Professor of Pediatrics at The Ohio State University College of Medicine. Dr. Flanigan is a principal investigator in the Center for Gene Therapy in The Research Institute at Nationwide Children’s, and a leading expert in Neuromuscular Disorders. The session will be moderated by Michael Kelly, Ph.D., Chief Scientific Officer at CureDuchenne.

Duchenne is a progressive muscle-wasting disease that impact 1 in 3,500 boys. Boys with Duchenne are usually diagnosed before the age of 5, in a wheelchair by age 12 and most don’t survive their mid-20s. There is currently no cure for Duchenne. CureDuchenne has funded seven research projects that have gone into human clinical trials.

To register for the “New Duplication Exon 2 Mouse Model: A Tool for Studies of Duplication Skipping for Duchenne” webinar on November 21, click here. 

Follow us on Facebook, Twitter and YouTube.

About CureDuchenne
CureDuchenne is a national nonprofit organization located in Newport Beach, Calif., dedicated to finding a cure for Duchenne, the most common and most lethal form of muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 boys worldwide.

CureDuchenne has garnered international attention for its efforts to raise funds and awareness for Duchenne through venture philanthropy. With the help of CureDuchenne’s distinguished international panel of Scientific Advisors, funds raised by CureDuchenne support the most promising research aimed at treating and curing Duchenne. To date, seven CureDuchenne research projects have made their way into human clinical trials – a unique accomplishment as few health-related nonprofits have been successful in being a catalyst for human clinical trials.

###